# Eurekam

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/eurekam

- Industry: Software
- Headquarters: La Rochelle, France
- Website: www.eurekam.fr
- Total disclosed funding: $1.1M
- Latest round: Series A (Dec 16, 2022)
- Investors on record: 1

## About

Eurekam SAS specializes in AI-driven solutions to enhance patient safety in medication preparation, particularly focusing on chemotherapy and vaccines to reduce medication errors in healthcare settings.Founded in 2012 in La Rochelle, France, Eurekam SAS develops solutions that enhance safety in medication preparation. The company was co-founded by Benoit Le Franc and Loïc Tamarelle and has raised EUR 1 million in its latest funding round. It has secured a total of EUR 1 million through 5 deals, with the most recent funding occurring on December 16, 2022, in a Venture Debt round.Eurekam specializes in the development of advanced artificial intelligence solutions aimed at enhancing patient safety in medication preparation. Their flagship product, Drugcam®, employs technology for automated verification and assistance in preparing injectable anticancer chemotherapy and anti-COVID-19 vaccines. This solution minimizes risks of medication errors, serving healthcare professionals such as oncologists and pharmacists across over 100 healthcare establishments in France, including hospitals and polyclinics.Eurekam's revenue model is based on business-to-business transactions with healthcare institutions adopting its Drugcam® technology. They engage clients through partnerships, offering subscription-based access to AI solutions tailored for specific healthcare needs, particularly for anticancer chemotherapy and vaccinations. This structure fosters long-term relationships with hospitals and pharmacies, ensuring recurring revenue streams through contractual agreements that outline service terms, including support and training for effective implementation.Eurekam plans to utilize the EUR 1 million raised in December 2022 to enhance and expand its product offerings, particularly targeting upcoming versions of Drugcam® designed for broader applications in healthcare. The company aims to enter new markets across Europe and is looking to expand its presence in the UK and Germany by 2024. These initiatives are part of a broader strategy to leverage recent funding to support R&D and marketing efforts aimed at increasing market penetration and customer acquisition.

## Funding rounds

- Series A, Dec 16, 2022, $1.1M — IMPACT partners

## Investors

- IMPACT partners — Series A